Hyperion Therapeutics Inc. (HPTX) reported a fourth-quarter net loss of $8.3 million or $0.50 per share, compared to a net loss of $8.7 million or $18.44 per share in the year ago quarter.
Weighted average number of shares used to compute net loss per share of common stock surged to 16.61 million from 469,319 last year.
Research and development expenses for the fourth quarter 2012 were $3.0 million compared with $3.5 million for the same period in 2011. The decrease for the quarter was primarily due to reduced clinical development and consulting expenses related to the company's HE Phase II trial and the long-term safety extension trial in adults with UCD both of which were largely completed in 2011.
For comments and feedback: editorial@rttnews.com